CA2426775A1 - Thienopyrimidine-based inhibitors of the src family - Google Patents

Thienopyrimidine-based inhibitors of the src family Download PDF

Info

Publication number
CA2426775A1
CA2426775A1 CA002426775A CA2426775A CA2426775A1 CA 2426775 A1 CA2426775 A1 CA 2426775A1 CA 002426775 A CA002426775 A CA 002426775A CA 2426775 A CA2426775 A CA 2426775A CA 2426775 A1 CA2426775 A1 CA 2426775A1
Authority
CA
Canada
Prior art keywords
hydrazone
pyrimidin
methylthieno
aromatic ring
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002426775A
Other languages
English (en)
French (fr)
Inventor
Michele A. Benish
Michael Lawless
Raymond J. A. Budde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2426775A1 publication Critical patent/CA2426775A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002426775A 2000-10-23 2001-10-23 Thienopyrimidine-based inhibitors of the src family Abandoned CA2426775A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/694,145 US6503914B1 (en) 2000-10-23 2000-10-23 Thienopyrimidine-based inhibitors of the Src family
US09/694,145 2000-10-23
PCT/US2001/050198 WO2002057271A2 (en) 2000-10-23 2001-10-23 Thienopyrimidine-based inhibitors of the src family

Publications (1)

Publication Number Publication Date
CA2426775A1 true CA2426775A1 (en) 2002-07-25

Family

ID=24787577

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002426775A Abandoned CA2426775A1 (en) 2000-10-23 2001-10-23 Thienopyrimidine-based inhibitors of the src family

Country Status (8)

Country Link
US (3) US6503914B1 (enExample)
EP (1) EP1409491A2 (enExample)
JP (1) JP2004517898A (enExample)
KR (1) KR20030040554A (enExample)
AU (1) AU2002246817B2 (enExample)
CA (1) CA2426775A1 (enExample)
MX (1) MXPA03003580A (enExample)
WO (1) WO2002057271A2 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334960B1 (en) * 1999-03-11 2002-01-01 Board Of Regents, The University Of Texas System Step and flash imprint lithography
WO2003064428A1 (en) * 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- and thienopyrimidines as neurokinase inhibitors
WO2003070241A1 (en) * 2002-02-15 2003-08-28 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
US7365103B2 (en) * 2002-12-12 2008-04-29 Board Of Regents, The University Of Texas System Compositions for dark-field polymerization and method of using the same for imprint lithography processes
US20040112862A1 (en) * 2002-12-12 2004-06-17 Molecular Imprints, Inc. Planarization composition and method of patterning a substrate using the same
US20040168613A1 (en) * 2003-02-27 2004-09-02 Molecular Imprints, Inc. Composition and method to form a release layer
US7122079B2 (en) 2004-02-27 2006-10-17 Molecular Imprints, Inc. Composition for an etching mask comprising a silicon-containing material
US7396475B2 (en) 2003-04-25 2008-07-08 Molecular Imprints, Inc. Method of forming stepped structures employing imprint lithography
US20060108710A1 (en) * 2004-11-24 2006-05-25 Molecular Imprints, Inc. Method to reduce adhesion between a conformable region and a mold
US7157036B2 (en) 2003-06-17 2007-01-02 Molecular Imprints, Inc Method to reduce adhesion between a conformable region and a pattern of a mold
US7307118B2 (en) * 2004-11-24 2007-12-11 Molecular Imprints, Inc. Composition to reduce adhesion between a conformable region and a mold
US20050160934A1 (en) * 2004-01-23 2005-07-28 Molecular Imprints, Inc. Materials and methods for imprint lithography
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
CA2532084A1 (en) * 2003-07-11 2005-02-03 Oregon Health And Science University Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US8557224B2 (en) * 2003-07-15 2013-10-15 Kao Corporation Oral cavity composition
US20050084804A1 (en) * 2003-10-16 2005-04-21 Molecular Imprints, Inc. Low surface energy templates
US7122482B2 (en) * 2003-10-27 2006-10-17 Molecular Imprints, Inc. Methods for fabricating patterned features utilizing imprint lithography
US20050107386A1 (en) * 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
ATE481134T1 (de) * 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
US8076386B2 (en) 2004-02-23 2011-12-13 Molecular Imprints, Inc. Materials for imprint lithography
US7906180B2 (en) 2004-02-27 2011-03-15 Molecular Imprints, Inc. Composition for an etching mask comprising a silicon-containing material
EP2298291A3 (en) 2004-06-18 2011-08-03 Agennix USA Inc. Kinase inhibitors for treating cancers
US20060004002A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors
US20060003980A1 (en) * 2004-07-02 2006-01-05 Shamsuddin Shaikh Cobalt(II) complexes as protein tyrosine kinase inhibitors
US20060004197A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
MX2007000631A (es) * 2004-07-16 2007-03-30 Sunesis Pharmaceuticals Inc Tienopirimidinas utiles como inhibidores de aurora cinasa.
US7282550B2 (en) * 2004-08-16 2007-10-16 Molecular Imprints, Inc. Composition to provide a layer with uniform etch characteristics
US7939131B2 (en) 2004-08-16 2011-05-10 Molecular Imprints, Inc. Method to provide a layer with uniform etch characteristics
WO2006029850A1 (en) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
US20060062922A1 (en) * 2004-09-23 2006-03-23 Molecular Imprints, Inc. Polymerization technique to attenuate oxygen inhibition of solidification of liquids and composition therefor
US20060081557A1 (en) * 2004-10-18 2006-04-20 Molecular Imprints, Inc. Low-k dielectric functional imprinting materials
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
US7292326B2 (en) 2004-11-30 2007-11-06 Molecular Imprints, Inc. Interferometric analysis for the manufacture of nano-scale devices
CA2619153C (en) * 2005-01-21 2013-12-31 President And Fellows Of Harvard College Regulation of protein synthesis by inhibition of eif4e-eif4g interaction
US8557351B2 (en) * 2005-07-22 2013-10-15 Molecular Imprints, Inc. Method for adhering materials together
US8808808B2 (en) 2005-07-22 2014-08-19 Molecular Imprints, Inc. Method for imprint lithography utilizing an adhesion primer layer
US7759407B2 (en) * 2005-07-22 2010-07-20 Molecular Imprints, Inc. Composition for adhering materials together
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US8142703B2 (en) * 2005-10-05 2012-03-27 Molecular Imprints, Inc. Imprint lithography method
WO2007056208A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
US20070099877A1 (en) * 2005-11-02 2007-05-03 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8288398B2 (en) * 2005-12-08 2012-10-16 Merck Serono Sa Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones
JP2009530401A (ja) 2006-03-24 2009-08-27 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ フェノールヒドラゾンマクロファージ転移阻害因子阻害剤
US20080110557A1 (en) * 2006-11-15 2008-05-15 Molecular Imprints, Inc. Methods and Compositions for Providing Preferential Adhesion and Release of Adjacent Surfaces
PT2412828E (pt) * 2007-03-13 2013-08-02 Amgen Inc Mutações k-ras e b-raf e terapia com anticorpos anti-egfr
RS53265B2 (sr) 2007-03-13 2022-06-30 Amgen Inc K-ras mutacije i terapija anti-egfr antitelom
EP2145014B1 (en) 2007-04-05 2012-12-12 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
US20100109195A1 (en) 2008-11-05 2010-05-06 Molecular Imprints, Inc. Release agent partition control in imprint lithography
KR101347303B1 (ko) 2010-01-29 2014-01-06 한미사이언스 주식회사 단백질 키나아제 저해활성을 갖는 티에노[3,2-ｄ]피리미딘 유도체
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
CN102250112A (zh) * 2010-05-18 2011-11-23 上海再启生物技术有限公司 7-溴-4-氨基噻吩并嘧啶的制备方法
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
CA2806572C (en) 2010-07-30 2018-10-30 Expression Pathology, Inc. C-src selected reaction monitoring assay
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
JP6120311B2 (ja) * 2013-02-12 2017-04-26 学校法人銀杏学園 ポリフェノール化合物
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
JP6978003B2 (ja) * 2015-12-03 2021-12-08 チョーチアン チアンフェン−イエン バイオテクノロジー カンパニー リミテッド 複素環式化合物およびその使用
JP6978002B2 (ja) * 2015-12-03 2021-12-08 チョーチアン チアンフェン−イエン バイオテクノロジー カンパニー リミテッド チエノ−ピリミジン誘導体およびその使用
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2019200221A1 (en) * 2018-04-13 2019-10-17 The University Of Toledo Necroptosis inducers or autophagy inhibitors or a combination thereof
WO2022099284A1 (en) * 2020-11-05 2022-05-12 Young Biopharma, Llc Novel capsaicin analogs and uses thereof
WO2025140721A1 (zh) * 2023-12-28 2025-07-03 粤港澳大湾区精准医学研究院(广州) 腙类化合物、其药物组合物及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1057612B (de) 1955-08-26 1959-05-21 Bodo Lehmann Kraftmaschine zur Erzeugung einer Drehbewegung durch ein Gas-, Dampf- oder Fluessigkeits-Druckmedium oder fuer den umgekehrten Prozess
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
FR2447494A1 (fr) 1979-01-24 1980-08-22 Mecanismes Comp Ind De Dispositif de reglage de la position d'un element deplacable dans un vehicule, tel que le siege de celui-ci
CH635167A5 (de) 1979-01-25 1983-03-15 Sulzer Ag Einspritzeinrichtung eines dieselmotorzylinders.
GB2043061B (en) * 1979-03-05 1983-05-11 Ici Ltd Thienopyrimidine and quinazoline derivatives
JPS5942387A (ja) 1982-07-21 1984-03-08 Sankyo Co Ltd チエノピリミジン誘導体および殺虫、殺ダニ剤
EP0196524B1 (en) 1985-03-14 1990-03-07 Sankyo Company Limited Phenoxyalkylaminopyrimidine derivatives, their preparation and insecticidal and acaricidal compositions containing them
DE3716131A1 (de) 1987-05-14 1988-12-01 Forsch Borstel Inst Fuer Exper Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel
JPH0720943B2 (ja) 1988-08-19 1995-03-08 宇部興産株式会社 アミノピリミジン誘導体、その製法及び殺虫・殺菌剤
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
US5877178A (en) * 1991-04-08 1999-03-02 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
EP0519211A1 (de) 1991-05-17 1992-12-23 Hoechst Schering AgrEvo GmbH Substituierte 4-Aminopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
WO1996014319A1 (en) 1994-11-08 1996-05-17 Takeda Chemical Industries, Ltd. Thienopyridine or thienopyrimidine derivatives and their use
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
WO1997009878A1 (en) 1995-09-15 1997-03-20 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6255310B1 (en) * 1996-02-07 2001-07-03 Neurocrine Biosciences Inc. Thiophenopyrimidines
EP1028964A1 (en) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6451792B1 (en) 1998-09-22 2002-09-17 Ishihara Sangyo Kaisha Ltd. Medical composition containing nitroetheneamine derivative or salt thereof as active constituent
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
CN1360582A (zh) 1999-07-07 2002-07-24 阿斯特拉曾尼卡英国有限公司 喹唑啉衍生物
US6313168B1 (en) * 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US6276782B1 (en) 2000-01-11 2001-08-21 Eastman Kodak Company Assisted drop-on-demand inkjet printer
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
US20060004002A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2002057271A3 (en) 2003-01-30
MXPA03003580A (es) 2005-04-08
EP1409491A2 (en) 2004-04-21
US20040077663A1 (en) 2004-04-22
KR20030040554A (ko) 2003-05-22
US7285556B2 (en) 2007-10-23
AU2002246817B2 (en) 2007-07-26
WO2002057271A2 (en) 2002-07-25
USRE39267E1 (en) 2006-09-05
JP2004517898A (ja) 2004-06-17
US6503914B1 (en) 2003-01-07

Similar Documents

Publication Publication Date Title
CA2426775A1 (en) Thienopyrimidine-based inhibitors of the src family
AU2002246817A1 (en) Thienopyrimidine-based inhibitors of the SRC family
CN112521387B (zh) Nlrp3调节剂
ES2338234T3 (es) Composiciones utiles como inhibidores de proteinas quinasas.
TWI805664B (zh) Ｔｌｒ７/８拮抗劑及其用途
JP5770102B2 (ja) 複素環化合物と使用方法
RU2561109C2 (ru) Соединения и способы применения
KR102652052B1 (ko) 이미다졸로닐 퀴놀린 및 atm 키나아제 저해제로서의 이의 용도
KR100840727B1 (ko) 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
CN101039944B (zh) 具有cdk1抗增殖活性的1,5-二氮杂萘唑烷酮类
CN104098551B (zh) 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
TW202116751A (zh) Ｈｐｋ１抑制劑及其用途
US20090214529A9 (en) Kinesin inhibitors
CN113166065A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
KR101921764B1 (ko) 피라졸로-퀴놀린
CA2412345A1 (en) Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
MX2012011045A (es) Novedosos derivados de indolina sustituidos.
TW202600136A (zh) Ｐｉ３ｋ抑制劑及其用途
EP2867237A1 (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
JP2020506904A (ja) キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
JP2022517111A (ja) がんの治療に用いるためのヘテロ環ｎｌｒｐ３モジュレーター
JP2022517110A (ja) がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン
Rana et al. Synthesis, in vitro anticancer and antimicrobial evaluation of novel substituted dihydropyrimidines
CN100569773C (zh) 作为抗癌剂的新型吖吲哚噻唑啉酮
AU2016245434B2 (en) Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued